Abstract: The present invention relates to a cyclic peptide, its use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
February 28, 2018
Date of Patent:
October 4, 2022
Assignee:
advanceCOR GmbH
Inventors:
Hans-Peter Holthoff, Martin Ungerer, Julia Fassbender, Zhongmin Li
Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
July 27, 2021
Assignee:
ADVANCECOR GMBH
Inventors:
Heidrun Degen, Silvia Goebel, Kristin Adler, Martin Ungerer
Abstract: The present invention relates to a cyclic peptide, its use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.
Type:
Application
Filed:
February 28, 2018
Publication date:
March 5, 2020
Applicant:
advanceCOR GmbH
Inventors:
Hans-Peter Holthoff, Martin Ungerer, Julia Fassbender, Zhongmin Li
Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.
Type:
Application
Filed:
April 6, 2011
Publication date:
May 23, 2013
Applicant:
ADVANCECOR GMBH
Inventors:
Meinrad Gawaz, Tanja Schönberger, Heidrun Degen, Götz Münch, Hans-Peter Holthoff, Andreas Bültmann, Hans-Jörg Bühring, Christoph Leder